泰国扩大免疫规划中使用的五价DTwP-HB-Hib疫苗(Shan-5)与六价DTaP-HB-Hib-IPV疫苗及DTwP-HB-Hib(Quinvaxem)疫苗在2、4、6月龄婴儿中接种的免疫原性比较
研究前瞻性纳入完成三剂Shan-5疫苗接种的儿童,比较Shan-5、六价疫苗和Quinvaxem疫苗的免疫原性。结果显示,Shan-5组与六价组抗-HBs几何平均浓度相当,均高于Quinvaxem组;基础免疫后1个月,Shan-5组抗-DT、抗-TT和抗-PT IgG水平显著高于其他两组。
要点
- 四剂免疫后1个月,Shan-5组、六价组和Quinvaxem组抗-HBs≥10 mIU/mL的比例分别为100%、99.2%和99.2%。
- Shan-5组与六价组抗-HBs几何平均浓度相当,均高于Quinvaxem组。
- 基础免疫后1个月,Shan-5组抗-DT、抗-TT和抗-PT IgG水平显著高于六价组和Quinvaxem组。
核心结论
- Shan-5疫苗中乙型肝炎表面抗原的免疫原性与六价疫苗相似,但高于Quinvaxem疫苗。
- Shan-5疫苗具有高度免疫原性,基础免疫后产生稳健的抗体应答。
研究设计与样本
- 在泰国叻丕府Regional Health Promotion Centre 5前瞻性纳入完成三剂Shan-5疫苗接种的儿童,于2020年5月至2021年5月期间进行。
- 在7月龄和18月龄采血,使用市售酶联免疫吸附试验检测抗-HBs、抗-DT IgG、抗-TT IgG和抗-PT IgG水平。
主要发现
- 四剂免疫后1个月,Shan-5组、六价组和Quinvaxem组抗-HBs≥10 mIU/mL的比例分别为100%、99.2%和99.2%。
- Shan-5组和六价组的抗-HBs几何平均浓度相当,均高于Quinvaxem组。
- 基础免疫后1个月,Shan-5组的抗-DT IgG、抗-TT IgG和抗-PT IgG水平显著高于六价组和Quinvaxem组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The pentavalent DTwP-HB-Hib (Shan-5) vaccine was first introduced into the Thailand Expanded Program on Immunization (EPI) in 2019. The Shan-5 vaccine is administered to infants at 2, 4, and 6 months of age, after initial vaccination with monovalent hepatitis B (HepB) and Bacillus Calmette-Guérin (BCG) vaccines at birth. This study compared the immunogenicity of the HepB, diphtheria, tetanus, and Bordetella pertussis antigens incorporated in the EPI Shan-5 vaccine versus the optional pentavalent (DTwP-HB-Hib) Quinvaxem and hexavalent (DTaP-HB-Hib-IPV) Infanrix-hexa vaccine. METHODS: Three-dose Shan-5-vaccinated children were prospectively enrolled at the Regional Health Promotion Centre 5, Ratchaburi province, Thailand, between May 2020 and May 2021. Blood sampling was performed at months 7 and 18. The levels of HepB surface antibody (anti-HBs), anti-diphtheria toxoid (DT) IgG, anti-tetanus toxoid (TT) IgG, and anti-pertussis toxin (PT) IgG were evaluated using commercially available enzyme-linked immunoassays. RESULTS: Anti-HBs levels of ≥10 mIU/mL were achieved in 100 %, 99.2 %, and 99.2 % of infants in the Shan-5 EPI group, hexavalent group and Quinvaxem group one month after four dose immunization (at 0, 2, 4, 6 months of age), respectively. The geometric mean concentrations of the EPI Shan-5 and hexavalent groups were comparable but were higher than those of the Quinvaxem group. At one month after primary vaccination (month 7), infants in the Shan-5 EPI group had significantly higher levels of anti-DT IgG, anti-TT IgG, and anti-PT IgG than infants in the hexavalent and Quinvaxem groups. CONCLUSIONS: The immunogenicity of the HepB surface antigen in the EPI Shan-5 vaccine was similar to that achieved by the hexavalent vaccine, but was higher than that achieved by the Quinvaxem vaccine. The Shan-5 vaccine is highly immunogenic and generates robust antibody responses after primary immunization.
引用
- Wanlapakorn N, Pruetarat N, Sarawanangkoor N, et al. Immunogenicity of the pentavalent DTwP-HB-Hib vaccine (Shan-5) used in the Thai Expanded Program on Immunization compared to the hexavalent DTaP-HB-Hib-IPV and DTwP-HB-Hib (Quinvaxem) vaccines administered to infants at 2, 4, 6 months of age. Vaccine. 2023. PMID: 37202270. doi:10.1016/j.vaccine.2023.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。